{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:08:41Z","timestamp":1792552121666,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1053\/j.ajkd.2014.10.005","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T07:36:50Z","timestamp":1416296210000},"page":"354-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD"],"prefix":"10.1053","volume":"65","author":[{"given":"Mark J.","family":"Sarnak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Saland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 suppl 3","key":"10.1053\/j.ajkd.2014.10.005_bib1","first-page":"I","article-title":"K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease","volume":"41","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.005_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1053\/j.ajkd.2014.10.005_bib3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9784","key":"10.1053\/j.ajkd.2014.10.005_bib4","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"25 suppl 2","key":"10.1053\/j.ajkd.2014.10.005_bib5","first-page":"S1","article-title":"2013 ACC\/AHA\u00a0guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force\u00a0on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.005_bib6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2215\/CJN.10271110","article-title":"Chronic kidney disease as a coronary disease equivalent\u2014a comparison with diabetes over a decade","volume":"6","author":"Debella","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.005_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.ajkd.2014.03.013","article-title":"Impact of age on the association between CKD and the risk of future coronary events","volume":"64","author":"Tonelli","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.005_bib8","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2014.10.005_bib9","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid managment in chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.005_bib10","doi-asserted-by":"crossref","first-page":"c171","DOI":"10.1159\/000325669","article-title":"Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction","volume":"119","author":"Chang","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.005_bib11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ahj.2012.09.003","article-title":"Cardiovascular risk assessment: addition of CKD and race to the Framingham equation","volume":"164","author":"Drawz","year":"2012","journal-title":"Am Heart J"},{"issue":"8","key":"10.1053\/j.ajkd.2014.10.005_bib12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.5551\/jat.19356","article-title":"Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita Study","volume":"21","author":"Nishimura","year":"2014","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.005_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease","volume":"50","author":"Weiner","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.005_bib14","doi-asserted-by":"crossref","first-page":"552.e1","DOI":"10.1016\/j.amjmed.2006.05.054","article-title":"Kidney disease, Framingham risk scores, and cardiac and mortality outcomes","volume":"120","author":"Weiner","year":"2007","journal-title":"Am J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.005_bib15","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2215\/CJN.07290810","article-title":"Kidney function and long-term medication adherence after myocardial infarction in the elderly","volume":"6","author":"Chang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.005_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/01.hco.0000126978.03828.9e","article-title":"Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients","volume":"19","author":"Krousel-Wood","year":"2004","journal-title":"Curr Opin Cardiol"},{"issue":"5","key":"10.1053\/j.ajkd.2014.10.005_bib17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/0193945912439251","article-title":"Accuracy of measures of medication adherence in a cholesterol-lowering regimen","volume":"34","author":"Dunbar-Jacob","year":"2012","journal-title":"West J Nurs Res"},{"issue":"9753","key":"10.1053\/j.ajkd.2014.10.005_bib18","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1053\/j.ajkd.2014.10.005_bib19","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) Study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1053\/j.ajkd.2014.10.005_bib20","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-148-9-200805060-00005","article-title":"Monitoring cholesterol levels: measurement error or true change?","volume":"148","author":"Glasziou","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2014.10.005_bib21","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1053\/j.ajkd.2014.10.005_bib22","first-page":"CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"5","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"10.1053\/j.ajkd.2014.10.005_bib23","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2012.16817","article-title":"Age and association of kidney measures with mortality and end-stage renal disease","volume":"308","author":"Hallan","year":"2012","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2014.10.005_bib24","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"7555","key":"10.1053\/j.ajkd.2014.10.005_bib25","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/bmj.38814.566019.2F","article-title":"Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial","volume":"332","author":"Tonelli","year":"2006","journal-title":"BMJ"},{"issue":"5","key":"10.1053\/j.ajkd.2014.10.005_bib26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"54","author":"Colhoun","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"10.1053\/j.ajkd.2014.10.005_bib27","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.005_bib28","first-page":"195","article-title":"Dyslipidemia and nephrotic syndrome: recent advances","volume":"15","author":"Kronenberg","year":"2005","journal-title":"J\u00a0Ren Nutr"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.005_bib29","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.transproceed.2009.06.134","article-title":"Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival","volume":"41","author":"Diaz","year":"2009","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1053\/j.ajkd.2014.10.005_bib30","first-page":"451","article-title":"Metabolic disorders following kidney transplantation","volume":"22","author":"Phillips","year":"2012","journal-title":"J\u00a0Ren Nutr"},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.005_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/TP.0b013e318160254f","article-title":"Risk factors for cardiovascular events after successful renal transplantation","volume":"85","author":"Vanrenterghem","year":"2008","journal-title":"Transplantation"},{"issue":"4 suppl 7","key":"10.1053\/j.ajkd.2014.10.005_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2014.10.005_bib33","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kasiske","year":"2009","journal-title":"Am J Transplant"},{"issue":"9374","key":"10.1053\/j.ajkd.2014.10.005_bib34","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.005_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2005.05.014","article-title":"Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study","volume":"46","author":"Jardine","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"10.1053\/j.ajkd.2014.10.005_bib36","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2014.10.005_bib37","series-title":"OPTN\/SRTR 2011 Annual Data Report","year":"2012"},{"issue":"9","key":"10.1053\/j.ajkd.2014.10.005_bib38","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1600-6143.2004.00539.x","article-title":"CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus","volume":"4","author":"Lemahieu","year":"2004","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2014.10.005_bib39","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","article-title":"Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus","volume":"5","author":"Lemahieu","year":"2005","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.005_bib40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.DMPK-11-RG-096","article-title":"Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake","volume":"27","author":"Shitara","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"issue":"7","key":"10.1053\/j.ajkd.2014.10.005_bib41","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.transproceed.2009.07.094","article-title":"Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion","volume":"41","author":"Sayin","year":"2009","journal-title":"Transplant Proc"},{"issue":"suppl 5","key":"10.1053\/j.ajkd.2014.10.005_bib42","first-page":"S213","volume":"128","year":"2011","journal-title":"Pediatrics"},{"issue":"24","key":"10.1053\/j.ajkd.2014.10.005_bib43","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1161\/CIRCULATIONAHA.106.179568","volume":"114","author":"Kavey","year":"2006","journal-title":"Circulation"},{"issue":"12","key":"10.1053\/j.ajkd.2014.10.005_bib44","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2215\/CJN.03010311","article-title":"Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease","volume":"6","author":"Wilson","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4, pt 1","key":"10.1053\/j.ajkd.2014.10.005_bib45","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1542\/peds.111.4.e382","article-title":"Epidemiology of chronic renal failure in children: data from the ItalKid project","volume":"111","author":"Ardissino","year":"2003","journal-title":"Pediatrics"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.005_bib46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1399-3046.2007.00704.x","article-title":"Contributions of the Transplant Registry: the 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)","volume":"11","author":"Smith","year":"2007","journal-title":"Pediatr Transplant"},{"issue":"1 suppl 1","key":"10.1053\/j.ajkd.2014.10.005_bib47","first-page":"e1","article-title":"US Renal Data System 2013 annual data report","volume":"63","author":"Collins","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2014.10.005_bib48","unstructured":"US Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (includes Special Request, Table\u00a0H.13 Combined Transplant and Dialysis Groups). USRDS Coordinating Center UR. http:\/\/www.usrds.org. Accessed August 7, 2008."},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.005_bib49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1523-1755.2002.00156.x","article-title":"Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study","volume":"61","author":"Groothoff","year":"2002","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.005_bib50","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1046\/j.1523-1755.2003.00814.x","article-title":"Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study","volume":"63","author":"Gruppen","year":"2003","journal-title":"Kidney Int"},{"issue":"26","key":"10.1053\/j.ajkd.2014.10.005_bib51","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMoa031643","article-title":"Long-term survival of children with end-stage renal disease","volume":"350","author":"McDonald","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2014.10.005_bib52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1681\/ASN.2012121197","article-title":"BP control and left ventricular hypertrophy regression in children with CKD","volume":"25","author":"Kupferman","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2014.10.005_bib53","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00467-010-1511-4","article-title":"Improvement of left ventricular mass with antihypertensive therapy in children with hypertension","volume":"25","author":"Kupferman","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2014.10.005_bib54","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2215\/CJN.03130312","article-title":"Carotid intima-media thickness in children with CKD: results from the\u00a0CKiD Study","volume":"7","author":"Brady","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.005_bib55","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/00912700222011346","article-title":"Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome","volume":"42","author":"Appel-Dingemanse","year":"2002","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"20","key":"10.1053\/j.ajkd.2014.10.005_bib56","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1053\/j.ajkd.2014.10.005_bib57","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2215\/CJN.00780306","article-title":"Management of dyslipidemias in patients with diabetes and chronic kidney disease","volume":"1","author":"Molitch","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2014.10.005_bib58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.005_bib59","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1525-139X.2009.00661.x","article-title":"Causes of dysregulation of lipid metabolism in chronic renal failure","volume":"22","author":"Vaziri","year":"2009","journal-title":"Semin Dial"},{"issue":"8","key":"10.1053\/j.ajkd.2014.10.005_bib60","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00467-007-0467-5","article-title":"Lipoprotein metabolism in chronic renal insufficiency","volume":"22","author":"Saland","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2014.10.005_bib61","first-page":"S14","article-title":"American Diabetes Association. Standards of medical care in diabetes\u20142014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.005_bib62","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4158\/EP.18.2.269","article-title":"American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary","volume":"18","author":"Jellinger","year":"2012","journal-title":"Endocr Pract"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614012839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614012839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:34:20Z","timestamp":1759458860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638614012839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0272638614012839"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.10.005","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}